Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2025 Earnings Call Transcript

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2025 Earnings Call Transcript February 25, 2026

Recursion Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.20528, expectations were $-0.28.

Najat Khan: Good morning, and thank you so much for joining us. I want to start by briefly framing where Recursion Pharmaceuticals, Inc. is today in its journey and evolution. Over the past decade, Recursion Pharmaceuticals, Inc. has built something truly special: a differentiated...